Q4 2024 IHH Healthcare Bhd Earnings Call Transcript
Key Points
- IHH Healthcare Bhd (XKLS:5225) reported double-digit growth in revenue and EBITDA for FY 2024, driven by increased patient volumes and higher revenue intensity across all markets.
- The company declared a total dividend of MYR0.10 for FY 2024, an 11% increase from the previous year, distributing about 40% of PATMI, which is above the 30% required by their dividend policy.
- IHH Healthcare Bhd expanded its operational capacity by adding close to 1,000 new beds across its markets, including acquisitions of Island Hospital and Timberland.
- The company introduced innovative treatments, such as hyperthermia for cancer treatment in Singapore, enhancing its clinical excellence.
- Strong cash flows from operating activities supported the company's brownfield expansion plans and recent acquisitions, such as Timberland and Island Hospital.
- PATMI was down compared to the previous year due to one-off costs, including the sale of the IMU asset and Gleneagles Chengdu.
- The Singapore operations faced capacity constraints due to renovations at Mount Elizabeth Orchard, impacting financial performance.
- There was a notable increase in finance costs, partly due to the acquisition of Island Hospital, which added to interest expenses.
- The company faced challenges with medical inflation in Malaysia, which is higher than in other markets, affecting cost management.
- Insurance companies in Malaysia are exerting pressure for discounts, which could impact revenue and margins if not managed effectively.
Ladies and gentlemen, good morning, and welcome to the fourth quarter and full year 2024 financial results of IHH Healthcare's analyst criefing conference call. (Operator Instructions)
I must advise you that this conference is being recorded today, February 28, 2025. I would now like to hand the call over to your first speaker today, Mr. Kelvin Chong from Investor Relations at IHH. Please go ahead, Mr. Chong.
Thank you. Good morning, and welcome. Thank you for joining us. I'm Kelvin from Group Investor Relations. With me today, Dr. Prem, our Group CEO; Dilip, our Group CFO; Ashok, Group Chief Corporate Officer. And joining us virtually is our Deputy CEO of Strategy and Business Development, (inaudible).
This is available via call and live webcast. Results are also available for download on the website. We'll begin with an opening to Dr. Prem give you high-level highlights on the group's performance, followed by a detailed financial status and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
